tbuckley/cabot-search huggingface dataset:
Multicentric phase II study of epirubicin and docetaxel as first line treatment for patients with advanced gastric cancer: A GERCOR study
Authors: S. Nguyen, M. Flesch, M. Bennamoun, F. Salle, E. Angellier, E. Carola, J. F. Berdah, S. Cattan, E. Magherini, C. Louvet
Journal: Journal of Clinical Oncology (2004)

4062 Background: Epirubicin and docetaxel (Epitax) are active as second-line treatment of patients with advanced gastric cancer resistant to cisplatin-based combination (Louvet et al, ASCO 1999). This multicentric phase II study was performed to evaluate the efficacy and safety of this combination in chemo-naive patients with locally advanced (LA) or metastatic(M) gastric cancer. Methods: 36 patients (7 females,29 males; performance status [PS] 0/1/2: 12/8/6, LA/M: 7/29; mean weight: 69,6 kg) were treated with epirubicin 60 mg/m2 in 30 minutes, followed 1 h later by docetaxel 75 mg/m2 in 60 minutes, every 21 days, in an outpatient basis . Corticosteroids were administered from day-1 to day 4, and GCSF recommended from day 3 to day 9. All patients were assessable for toxicity (NCI-CTC criteria) and efficacy (Recist evalution criteria). Patients were evaluated every 3 cycles (2 months), and 5FU + platinium-based second-line treatment was recommended at progression. Results: 174 cycles were administered (median 5, range 1–9). No toxic death was reported. Grade 3–4 toxicities were: neutropenia in 41,7% of patients,thrombocytopenia in 5,6%, anemia in 11,1%, nausea-vomiting in 13,9% and diarrhea in 5,6%. Median PS and mean weight remained unchanged at first evaluation. Symptoms (including pain,anorexia and dysphagia ) were improved at first evaluation in one-third of patients with initial symptoms. 1 complete response (CR) (2,7%) and 6 partial response (PR) (16.7%) were obtained, for an overall response (OR) rate of 19,4% (95% CI: 0,07–0,32). 10 patients (27,8%) had stable disease, and 19 patients (52,8%) progressed. Two-third of patients received second-line therapy. With a median follow-up time of 100 weeks, the median PFS and OS times were 18 and 52 weeks, respectively. Conclusions: First-line efficacy of EPITAX combination is in the same range as that observed in second-line, with an acceptable toxicity. 1-yr overall survival may be related to the therapeutic strategy including early evaluation and active second-line therapy. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis France Sanofi
Primer Sklerozan Kolanjitte Magnetik Rezonans ve Endoskopik Retrograd Kolanjiyografinin Diagnostik Doğruluğu
Authors: Audun Elnaes Berstad, Lars Aabakken, Hans-Jørgen Smith, Steinar Aasen, Kirsten Muri Boberg, sup> Ve Erik Schrumpf ‡<
Journal: Clinical Gastroenterology and Hepatology (2006)
WHO Survey of Prevalence of Mental Health Disorders
Authors: Robert D Goldney, Laura J Fisher, Graeme Hawthorne
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 12091: Novel ECMO Cannulation Strategy Expedites Conversion to LVAD
Authors: Lisa S Foley, T. B Reece, Andreas Brieke, Amrut Ambardekar, Joseph C Cleveland, Ashok N Babu, David A Fullerton
Journal: Circulation (2014)

Objectives: Venoarterial (VA) ECMO has emerged as a successful modality for bridging patients with critical cardiogenic shock to durable support. However, LV distention on ECMO impairs RV and lung recovery and can result in the need for a temporary RVAD. Additionally, patients on VA ECMO with organ dysfunction may require ongoing LV assistance for recovery prior to durable LVAD conversion. Placement of a large apical LV vent allows bedside conversion to LVAD and provides time for organ recovery prior to elective durable device implantation. Hypothesis: We hypothesized that LV venting on ECMO accelerates RV recovery, hastening conversion to LVAD. Methods: ECMO cases from January 2012 to April 2014 were reviewed following IRB approval. Sixteen patients met INTERMACS Category 1 criteria who were placed on VA ECMO for cardiogenic or post-cardiotomy shock. Eight patients had LV venting and eight had standard peripheral cannulation. Refractory pulmonary edema, CPR during cannulation, and severe LV distention were indications for LV venting. A 32 French malleable cannula was placed by limited anterolateral thoracotomy into the LV apex. Bedside LVAD conversion was performed by percutaneous decannulation of the venous line and removal of oxygenator from circuit. Results: Conversion to temporary LVAD was successful in all LV vent cases at a mean timepoint of 5.9 (±1.3) days after LV venting compared with 13.5 (±4.9) days in non-vented patients (p = 0.07). RVAD requirement was 25% in non-vented patients and 0% in vented patients. 30-day mortality was 25% for both groups. Conclusions: LV venting as an adjunct to VA ECMO facilitates RV recovery to enable early LVAD conversion at the bedside. It also provides organ recovery time and obviates the need for a temporary RVAD at the time of durable LVAD implantation. In conclusion, the LV apical venting technique allows staged recovery of critically ill patients in biventricular and multiple organ failure with a high survival rate.
An overview of unwanted female hair
Authors: U. Blume-Peytavi
Journal: British Journal of Dermatology (2011)

Unwanted facial hair (UFH) is an important but often overlooked issue, with over 40% of women experiencing some degree of UFH. In the female population a wide spectrum of unwanted hair concerns is represented – from biologically normal but undesirable to excessive unwanted hair with an underlying pathology. While women may seek to manage unwanted hair across their bodies, UFH is a particular concern, due to its negative impact on perceived femininity. There may not always be a direct correlation between degree of severity diagnosed objectively by the physician and level of concern and impact upon the patient. This review discusses the spectrum of facial hair experience and outlines the clinical approach to unwanted hair management including UFH. It highlights the importance of a treatment regimen which should respond to the causation factors and needs of the individual. This will lead to a holistic treatment approach including evaluation of the implementation of emotional coping strategies and on‐going support, lifestyle modifications, pharmacological interventions (to address underlying pathologies) and the use of cosmetic hair removal methods as either a stand‐alone or adjunct treatment as appropriate to the individual.
349. GM-CSF / IL-2 Fusion Transgene Is More Potent Than GM-CSF and IL-2 in Combination and Is Dependent upon CD8 and NK Cells for Antitumor Effect
Authors: John Stagg, Nathaniel Bouganim, Jacques Galipeau
Journal: Molecular Therapy (2004)

We have previously reported the engineering of a mouse GM-CSF and IL-2Fusion Transgene, or GIFT. The cDNA encoding the two cytokines was successfully cloned in frame as confirmed by sequencing analysis. B16 murine melanoma cells were gene modified using amphotropic retrovectors to express the bicistronic constructs encoding GIFT, GM-CSF or IL-2 and the GFP reporter. Our previous work demonstrated that: i) the GIFT gene product is present in the supernatant of gene-modified B16 cells, ii) the GIFT gene product is bi-functional, and iii) when GIFT is expressed by live B16 cells, the cells are promptly rejected in syngeneic hosts in a immune dependent manner.
Abstract 5010: Determining the Plasticity of Cardiovascular Risk in the Elderly: A role for serial NT-proBNP measurement
Authors: Christopher Defilippi, Robert Christenson, John Gottdiener, Willem J Kop, Stephen L Seliger
Journal: Circulation (2008)

In the elderly, with decades of exposure to cardiovascular (CV) risk factors, CV prognosis is often considered static. We hypothesized that CV risk is dynamic reflected by changes in NTproBNP over time. We measured NTproBNP at baseline and after 2–3 years in the Cardiovascular Health Study. Long-term risk of CV death according to change in NTproBNP was estimated with the Kaplan-Meier method. We used Cox models to test if effect of change in NTproBNP was independent of demographic and CV risk factors, baseline NTproBNP, renal function, coronary disease, and CV medications. Participants were categorized at baseline as &lt; (low) or &gt;=190pg/mL (high) levels, based on an observed increase in risk above this level. A significant change in NTproBNP category was defined as a change of &gt;25% to a level above or below this cut-point, based on the reported biological variability of NTproBNP. Change in NTproBNP was also evaluated as a continuous measure. Serial NTproBNP levels were measured in 2,975 (86%) of 3,469 participants (age 75±5 years) without heart failure and who had a follow-up visit. CV death was different between those with low levels that remained low (n=1,774) vs. those with low levels that became high (n=468) (1.1 vs. 2.7 per 100 person-yrs, p&lt;.001) and those with high levels that remained high (n=621) vs. those with high levels that became low (n=112) (4.2 vs. 1.6 per 100 person-yrs, p&lt;.001) (figure ). As a continuous measure, change in NTproBNP was linearly associated with CV mortality risk after adjustment (per Ln-fold increment: RR=1.47, p&lt;.001). Dynamic changes in NTproBNP levels reflect dramatic change in CV prognosis in the elderly. Proportion without Cardiovascular death, by initial and follow-up NT-proBNP
Abstract P274: A meta-analysis of meta-analyses: Is "reverse Epi" OK or not?
Authors: Ken Williams, Allan D Sniderman
Journal: Circulation (2014)

Introduction: Applications of observational risk models assuming “all else equal” to estimate the effect on risk of interventions expected to change the level of one or more independent variables have been criticized as “reverse Epi” since clinical trials provide better estimates of treatment effects. Hypothesis: The purpose of this analysis is to assess how reasonable it is to use “reverse Epi” to project the number of events avoided under different scenarios in which different markers are used for determining to whom to prescribe and how to target preventative treatment. We pursued this aim by comparing two different meta-analyses which compared HRs for apoB and non-HDL-C. One meta-analysis included 12 published observational studies. In 11 of these studies all subjects were at primary CHD risk. The other meta-analysis included 7 placebo-controlled statin trials (3 primary and 4 secondary). Methods: We calculated the reciprocal of each observational study’s HR per 1-SD increase (36 mg/dl for non-HDL-C and 27 mg/dl of apoB) to compare with each trials’ HR per 1-SD decrease; calculated the percentage difference (95% CI) in standard HRs for each report assuming a correlation between the two markers of 0.93 (calculated from NHANES 2005-2010 to be representative of adult US residents); and compared the resulting statistics using standard subgroup meta-analysis. Results: The overall geometric mean point estimate (95% CI) of the difference favoring apoB over non-HDL-C for all observational studies was 11.1% (7.7%, 14.4%) versus 5.4% (2.9%, 9.2%) for all 7 trials (p = 0.007). However these same point estimates are 9.5% (7.3%, 14.0%) versus 10.6% (7.3%, 14.0%) (p=0.714) when only primary studies or trials were included. The geometric mean treatment effect HR among the 4 secondary trials was 0.732 (0.689, 0.792) versus 0.599 (0.504, 0.714) among the 3 primary trials (p = 0.035). Conclusion: Meaningful differences between primary and secondary observational and interventional studies warrant stratified analysis. Among subjects at primary CHD risk, “reverse Epi” application of primary observational results may provide projections similar to those from applying primary trial results.
Abstract 17332: Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Death in Patients after an Acute Coronary Syndrome
Authors: Michelle L O’Donoghue, David A Morrow, Benjamin M Scirica, Jeremy Furtado, Jianping Guo, Dariush Mozaffarian, Marc S Sabatine
Journal: Circulation (2014)

Introduction:  Plasma omega-3 polyunsaturated fatty acids (Ω3-PUFA) have been inversely correlated with the risk of cardiovascular death in primary prevention populations. The prognostic value of Ω3-PUFA in patients with an acute coronary syndrome (ACS) is not well established.   Methods:  Baseline plasma Ω3-PUFA composition (including plant-derived ALA and the 3 long-chain marine-based Ω3-PUFAs EPA, DPA, & DHA) was assessed through thin liquid chromatography in a case control population (203 CV deaths & 1612 controls) from MERLIN-TIMI 36, a randomized trial of ranolazine versus placebo in patients hospitalized with an ACS. Median follow-up was 1 year. Analyses were adjusted for age, sex, BMI, traditional cardiac risk factors and cardiac history, lipids, renal function, and index diagnosis.   Results:  After multivariable adjustment, patients with higher plasma fractions of each Ω3-PUFA tended to have lower odds of CV death. When all 4 Ω3-PUFAs were combined, the highest fractional levels (Q4 vs Q1-Q3) of total Ω3-PUFA (OR 0.63, 0.41-0.97) and long-chain Ω3-PUFA (OR 0.58, 0.37-0.89) were significantly associated with reduced odds of CV death (Figure). In contrast, Ω3-PUFA plasma fraction was not significantly associated with the odds of MI, atrial fibrillation, or ventricular tachycardia.   Conclusions:  In patients after ACS, a higher proportion of plasma Ω3-PUFA is associated with lower odds of CV death, independent of traditional risk factors and lipids. These data support the rationale for ongoing studies to assess whether Ω3-PUFA supplementation will translate into a mortality benefit in this population.
Abstract P4-01-19: The combined detection of CTC and serum HER2 ECD predict PFS for HER2-positive advanced breast cancer patients
Authors: Zefei Jiang, Jinmei Zhou, Tao Wang, Yi Liu, Lei Li, Huiqiang Zhang, Shaohua Zhang, Li Bian, Santai Song
Journal: Cancer Research (2015)

Abstract Background: Circulating tumor cell (CTC) and serum HER2 ECD can all reflect an aggressive tumor behavior. We performed this prospective, monocenter, double-blinded study to investigate the potential clinical significance of combined detection of CTC and serum HER2 ECD for advanced breast cancer patients with histological HER2-positivity. Methods: A total of 88 eligible patients were enrolled in the present study from April 2012 to October 2013. We used Cell search system and ADVIA Centaur System to detect CTC and serum HER2 ECD respectively. Patients received systemic treatment according to national and international guidelines. Results: Twenty nine (33%) patients had ≥5 CTC, seventy three (83%) patients had serum HER2 ECD values of at least 15ng/ml, twenty seven (30.7%) patients had both elevated CTC and ECD values and fourteen (15.9%) patients had both normal CTC and ECD values. Patients with both normal CTC and serum HER2 ECD values exhibited a significantly longer median PFS than patients with both elevated values (9.0 months versus 2.8 months, p=0.023) and exhibited a trend toward longer PFS compared with patients with elevated CTC or ECD values (9.0 months versus 4.2 months, p=0.065), patients with both or one elevated values showed similar median PFS (2.8 months versus 4.2 months, p=0.211) (Figure1). Conclusions: The combined detection of CTC and serum HER2 ECD showed prognostic significance for HER-2 positive advanced breast cancer patients, patients with both normal values exhibited longer median PFS than others. Citation Format: Zefei Jiang, Jinmei Zhou, Tao Wang, Yi Liu, Lei Li, Huiqiang Zhang, Shaohua Zhang, Li Bian, Santai Song. The combined detection of CTC and serum HER2 ECD predict PFS for HER2-positive advanced breast cancer patients [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-01-19.
Walnuts and Endothelial Function in Hypercholesterolemic Subjects
Authors: Michael Shechter
Journal: Circulation (2004)

To the Editor:Ros et al 1 recently reported that substituting walnuts for monounsaturated fat in a Mediterranean-type diet improves endothelial function in hypercholesterolemic subjects.The investigators explain that nuts contain sizable amounts of antioxidants, as well as L-arginine and ␣-linolenic acid, which might also confer additional antiatherogenic properties.I should emphasize, however, that a walnut-enriched diet contains high magnesium levels (ie, 169 elements of magnesium per 100 g of nut).We previously demonstrated 2 that magnesium supplementation in patients with coronary artery disease (CAD) was associated with significant improvement in brachial artery endothelial function and exercise tolerance.Our group also demonstrated that oral magnesium supplementation inhibits platelet-dependent thrombosis in CAD patients, independent of platelet aggregation or P-selectin expression, and was evident despite aspirin therapy. 3Magnesium is also an antioxidant 4 and therefore may additively alter lipid profile and improve endothelial function.Therefore, the magnesium found in walnuts may explain some of the beneficial effects described by Ros et al.
Risk of asthma in adult twins with type 2 diabetes and increased body mass index
Authors: S. F. Thomsen, D. L. Duffy, K. O. Kyvik, A. Skytthe, V. Backer
Journal: Allergy (2010)

To cite this article: Thomsen SF, Duffy DL, Kyvik KO, Skytthe A, Backer V. Risk of asthma in adult twins with type 2 diabetes and increased body mass index. Allergy 2011; 66 : 562–568. Abstract Aim: To examine the relationship between asthma, type 2 diabetes and increased body mass index (BMI) in adult twins. Methods: We performed record linkage between questionnaire‐defined asthma and BMI, and hospital discharge diagnoses of type 2 diabetes in 34 782 Danish twins, 20–71 years of age. Results: The risk of asthma was increased in subjects with type 2 diabetes relative to nondiabetic subjects both in men (13.5% vs 7.5%), P = 0.001 and in women (16.6% vs 9.6%), P = 0.001. The result remained significant after adjustment for age, BMI, smoking, symptoms of chronic bronchitis, marital status and zygosity, men: OR = 1.70 (1.07–2.70), P = 0.026; women: OR = 1.88 (1.24–2.85), P = 0.003. In this analysis, BMI remained a highly significant predictor for asthma independently of diabetes status in women, P &lt; 0.000 but not in men, P = 0.336. Significant positive genetic correlations were found between asthma and type 2 diabetes, 0.20 (0.01–0.40), P = 0.047; between asthma and BMI in women, 0.15 (0.07–0.22), P &lt; 0.000; and between BMI and type 2 diabetes, 0.40 (0.29–0.43), P &lt; 0.000. Conclusions: Asthma, type 2 diabetes and increased BMI are strongly associated in adults, particularly in women. These results suggest a common aetiology for asthma and metabolic syndrome.
Abstract 43: Podoplanin in head and neck squamous cell carcinoma: Prognostic value and clinicopathological implications
Authors: Bon Seok Koo, Kyu Lim
Journal: Cancer Research (2014)

Abstract Background: Podoplanin is a mucin-type transmembrane glycoprotein that is important in lymphangiogenesis. We investigated the associations of podoplanin expression status with clinicopathological variables and the prognostic influence of podoplanin expression in head and neck squamous cell carcinoma (HNSCC), to determine its effectiveness as a marker of high-risk HNSCC subjects. Patients and Methods: We analyzed by immunohistochemistry podoplanin expression and its associations with the clinicopathological characteristics of 119 surgically treated HNSCC cases. Additionally, we investigated the effects of podoplanin expression on overall survival and disease-specific survival in univariate and multivariate analyses. Results: Of 119 HNSCC patients, high podoplanin expression was found in 61 cases (51.3%) and low expression in 58 (48.7%). High podoplanin expression was associated with lymph node metastasis, advanced AJCC stage, and poor histological grade (p &amp;lt; 0.05). In multivariate analysis, high podoplanin expression was significantly associated with circa three- and fivefold increases in the presence of positive lymph node metastasis and poor histological grade, respectively (p &amp;lt; 0.05). High levels of podoplanin expression were significantly associated with decreased overall survival and disease-specific survival (p &amp;lt; 0.05). Conclusions: Our findings suggest that high podoplanin expression is associated with aggressive tumor behavior and poor prognosis in HNSCC. Note: This abstract was not presented at the meeting. Citation Format: Bon Seok Koo, Kyu Lim. Podoplanin in head and neck squamous cell carcinoma: Prognostic value and clinicopathological implications. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 43. doi:10.1158/1538-7445.AM2014-43
Analytisches Diagnostikum: Die chemischen, mikroskopischen und bakteriologischen Untersuchungsmethoden VON Harn, Auswurf, Magensaft, Blut, Kot usw.
Authors: Ernst Kraft
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal